Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Roche Pulls Ahead in Oncology, Expected to Remain Market Leader Until 2023

By GBI Research | June 27, 2017

Roche will remain oncology market leader to 2023, in an increasingly fragmented but growing therapy area, says GBI Research.

None of the products due to enter the oncology market by 2023 are expected to reach the same levels of success as the highest revenue-generating drugs currently in the market—such as Revlimid, Opdivo, and Avastin—according to business intelligence provider GBI Research.

The company’s latest report states that the oncology landscape is now highly competitive, with entrenched products competing for market share even in the second-line segment of most indications. This means that the uptake of new products requires time, entailing a market share ramp-up period in excess of 10 years in some instances. In addition, the continuing trend towards treating targeted patient subsets means that the available market shares for newer drugs are more constrained.

However, there are a number of late-stage pipeline candidates that are expected to generate strong annual revenue during the forecast period, with the PD-1 inhibitor durvalumab and the CDK-4 and -6 inhibitor abemaciclib expected to achieve blockbuster revenues by 2023, according to GBI Research.

Newer CAR-T cell therapies Tisagenlecleucel-T and KTE-C19 are also expected to make an entry into the market and achieve blockbuster revenues during this period. Moreover, the exceptionally large overall pipeline, which consists of 7,701 products, points to continued long-term growth in the oncology market.

Dominic Trewartha, Managing Analyst for GBI Research, explains: “The key market players, namely Roche, Celgene, Bristol-Myers Squibb and Novartis, are forecast to achieve strong revenue growth throughout the market period, although the entry and growth of new players such as AstraZeneca, Pfizer and Merck means that their overall market shares are expected to decline.

“The oncology market shares of Roche, Celgene, Bristol-Myers Squibb, and Novartis are all anticipated to decrease substantially by 2023. Nevertheless, despite the approaching patent expiries of Roche’s Avastin, Kadcycla, Perjeta, and Tarceva, the company is expected to maintain the highest market share of any company, accounting for 25% of revenues in the oncology market, excluding generics, by 2023 – down from 45% in 2016.”

(Source: GBI Research)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50